Companies › Allist Pharmaceuticals
6 active drug programs in 31 registered trials: 13 Phase 2, 9 Phase 1, 8 Phase 3, 1 Phase 4; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Firmonertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Non-small Cell Lung Carcinoma; EGFR; NSCLC; Leptomeningeal Metastasis … | Dec 2026 |
| JAB-21822 KRAS G12C inhibitor | KRAS | Phase 3 | Advanced Non-squamous Non-small-cell Lung Cancer; KRAS P.G12C; Advanced Colorectal Cancer; NSCLC … | Dec 2026 |
| JAB-3312 SHP2 inhibitor | PTPN11 | Phase 3 | Advanced Non-squamous Non-small-cell Lung Cancer; KRAS P.G12C | Mar 2027 |
| Furmonertinib Mesilate Tablets EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | NSCLC Patients With Brain Metastasis | Mar 2029 |
| Alflutinib Mesylate (AST2818) EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | – |
| AST2303 Tablets (ABK3376 Tablets) | – | Phase 1 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03787992 | Alflutinib Mesylate (AST2818) | Phase 3 | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | Oncology | Sep 2021 |
| NCT06838338 | JAB-21822 | Phase 1 | Colorectal Cancer | Oncology | Mar 2026 |
| NCT06192849 | Firmonertinib | Phase 2 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT04853342 | Firmonertinib | Phase 3 | Non-small Cell Lung Carcinoma | Oncology | Dec 2026 |
| NCT05466149 | Firmonertinib | Phase 2 | NSCLC | Oncology | Dec 2026 |
| NCT06652048 | Firmonertinib | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05194995 | JAB-21822 | Phase 1 | Advanced Colorectal Cancer | Oncology | Dec 2026 |
| NCT05009329 | JAB-21822 | Phase 1 | NSCLC | Oncology | Dec 2026 |
| NCT06955988 | AST2303 Tablets (ABK3376 Tablets) | Phase 1 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06674343 | Firmonertinib | Phase 3 | Advanced or Metastatic Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06008288 | JAB-21822 | Phase 2 | KRAS P.G12C | Oncology | Dec 2026 |
| NCT05288205 | JAB-21822 | Phase 1 | KRAS P.G12C | Oncology | Mar 2027 |
| NCT05288205 | JAB-3312 | Phase 1 | KRAS P.G12C | Oncology | Mar 2027 |
| NCT07087223 | Firmonertinib | Phase 1 | Non Small Cell Lung Cancer NSCLC | Oncology | Apr 2027 |
| NCT07092202 | Firmonertinib | Phase 4 | Leptomeningeal Metastasis | Oncology | May 2027 |
| NCT05276726 | JAB-21822 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Aug 2027 |
| NCT06945705 | Firmonertinib | Phase 2 | NSCLC | Oncology | Sep 2027 |
| NCT07655622 | Firmonertinib | Phase 1 | Non-Small-Cell Lung Cancer | Oncology | Dec 2027 |
| NCT06956001 | Firmonertinib | Phase 3 | EGFR | Oncology | Dec 2027 |
| NCT07548060 | Firmonertinib | Phase 2 | NSCLC Stage IV | Oncology | Jan 2028 |
| NCT05334277 | Firmonertinib | Phase 2 | Non-small Cell Lung Cancer | Oncology | Feb 2028 |
| NCT05987826 | Firmonertinib | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Aug 2028 |
| NCT07010419 | Firmonertinib | Phase 3 | NSCLC | Oncology | Oct 2028 |
| NCT07304739 | Firmonertinib | Phase 2 | Non Small Cell Lung Cancer | Oncology | Dec 2028 |
| NCT05503667 | Firmonertinib | Phase 2 | Lung Adenocarcinoma Stage III | Oncology | Dec 2028 |
| NCT06970639 | Furmonertinib Mesilate Tablets | Phase 3 | NSCLC Patients With Brain Metastasis | Oncology | Mar 2029 |
| NCT06416410 | JAB-21822 | Phase 3 | Advanced Non-squamous Non-small-cell Lung Cancer | Oncology | Sep 2029 |
| NCT06416410 | JAB-3312 | Phase 3 | Advanced Non-squamous Non-small-cell Lung Cancer | Oncology | Sep 2029 |
| NCT05430802 | Firmonertinib | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2029 |
| NCT07622706 | Firmonertinib | Phase 2 | NSCLC | Oncology | Dec 2029 |
| NCT07314216 | Firmonertinib | Phase 2 | NSCLC (Non-small Cell Lung Carcinoma) | Oncology | Dec 2030 |
HUYABIO International Jiangsu Alphamab Biopharmaceuticals Rakuten Medical Genfleet Therapeutics (Shanghai) Nanjing Sanhome Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.